Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look up power of attorney on those patents. Medtronic has it and all documentation and prosecution goes through them.
“They are paying for technology still in development so very unlikely the patents have been approved already” - Let him go he’s on a roll
Wrong…. Again. They licensed patents that were already granted. They are developing patents for the mutual benefit of both companies. I’m gonna start calling you Mr Blutarsky but that might not be fair to Mr Blutarsky.
You mention indications versus evidence with an attempt to show your intellect. In the next sentence you say ALL indications, and show your lack of intellect. I’m not even gonna get into evidence versus indications….. not worth it. Mac doing investors conferences could be an INDICATION that he wants institutional investor eyes on Titan as he’s about to release results of GLP studies and Milestone 4 and his CFO said to those same investors that another raise isn’t coming until around IDE 2022. That was what was publicly stated. Those indications don’t indicate they are going alone anymore than they will be bought. And you are wrong again. They are not hiring a COO. Just as with IREP wrong again. But to that point, INDICATIONS are they are building out a company to turn over to the buyer. Can you opine why they may want to do this? Why would a medtronic, JNJ, Olympus want a full R and D and manufacturing team in place prior to buyout?
Says the guy that thinks this is selling for 200 million
So what’s your next move?
You are wasting your time. There’s very few traders here. Longs are white knuckling it holding onto their shares. There is no incentive to tax loss sell because all longs have already done that and newbies have profits, they are on record saying no raise until IDE and they are knocking on the door of some monumental milestones that will tell the tale of where this is going. Your play should be vicarious right now. Once the VC’s pull out of that thing it will drop like a lead balloon, then they have to dilute for the next 4 years. It will be like you guys were starting over with Titan 4-5 years ago. Fertile ground.
Show us where he did that.
That was the CFO 2 CFOs ago. Living in the past again. Same as IREP.
You aren’t comparing apples to apples. Firstly, you can’t compare vicarious to IREP as we have had to reiterate that ad nauseum. They are no longer using IREP. It’s not patentable and it is inferior to what Titan is currently using. Secondly, the arms are make believe. They aren’t going to be able to use the arms as constructed as they clearly violate Intuitives IP. Those elbows appear to be a real problem. The camera doesn’t compare. There is no camera when you are entering the body. They don’t have lights on the insertion tube that light up the body cavity. Do they have augmented reality like Titan? Do they have haptics like Titan? Surely you have these answers if you can confidently say they have a clear technological advantage over Titan?
Mr Fowler left because they were no longer moving forward with IREP and platform imaging camera(both his babies). It was right after IREP was found to be in unpatentable and they realized it was inferior technology. So for you investors that follow Titan closely ;) please note that platform imaging is no longer part of the robot.
So if they went bankrupt they(MDT) already have the licensed IP and could take the tech for pennies on the dollar. Why would they care?
Common place to have a board observers when licensing from another company? Does that make business sense to you?
Yeah that’s why they have a board observer.
Well, looks like the market liked it! Shorts are gonna have to really work as this may become a run away train soon.
It was a yawner IMO. The tweaking of the presentation is something that was long overdue, basically telling investors what’s in it for them versus the clinical/engineering pitch he usually gives to a bunch of money people that don’t really care about that. Q4 milestone by end of year. De Novo route confirmed by FDA. Submission early 2023 and approval late 2023. IDE coming soon with 30+ case human trials at 3-4 centers. Very protected by patents commenting that they precede many other SP RAS in the space. Also mentioned they are one of the few Authentic SP players in the space(paraphrasing). He’s a little too conservative in these presentations IMO. Oh and money to take them to end of 2022.
Titan will be bought by a large strategic because they are patent protected. That is why they are valuable because they can defend themselves with patents.
500 million hahaha. Last I checked Intuitive has a $122 BILLION market cap and $6 BILLION cash on hand but unlike you I’m not a patent attorney so I will defer to your qualified opinion
Arms, end effectors, access….. it is you who may want to look into that
If it was Medtronic or JNJ possibly but a vicarious litigating versus an Intuitive? I find it hard to believe they will be able to drag that out years without dire consequences but I’m not a patent attorney. If there are any on this board please weigh in.
Told you will never waste my time again doing your homework for you. You questioned and had a good laugh at me for claiming that Medtronic was licensing the arms and camera from Titan. I sent the proof and you deleted it. Well what do you know looks like we now know for sure, and btw, it wasn’t the only thing they licensed.
Doesn’t matter if you can’t collect revenue related to those arms. They might want to look into intuitive patents on the arms.
Still very involved
Looking at last year during all the tax loss harvesting TMDI went from $.74 on Sept 4 to $1.71 on 12/31. Surely you have more than that.
You mean Road Shows
The i warrants expire.
No. It’s not September 21st yet
Not sure I agree here. They have enough resources where they can juggle both projects simultaneously if need be. That being said I have no idea when they step in and say we’ll take it from here boys.
You bring up an interesting point regarding Stealth. I don’t know much about it. Was this created by Medtronic or did they buy this technology?
$1.18. They can’t get it to $1.50. Honeycomb has left the building. He’s onto something that he can move.
Serious crippling IP issues imo
End of 2023, but still a long time
Haha. He put a million dollars into it. He regularly bets on loser stocks as another poster posted a week or two ago. That would be like me throwing $100 into a stock
Nothing wrong with putting your money in a good S & P 500 index fund
Shorts are failing miserably. Funny to watch really
Again, did not sell their IP.
You valued the company at 200-300 million. We’ll answer those questions when you explain your valuation.
Ok the new number is under $1. Noted. Let’s see if you guys can get us there. As for valuation, you are wrong, IMO. Here is why. We have two recent easy comps in which to properly value Titan. Memic and Vicarious are both single port offerings. Both valued at a billion dollars by the SPACs that they reverse merged into. Memic is a single port without a camera, has about 20 patents and may have significant patent issues with its snake like arms. Vicarious is years(4-5 years) from FDA approval has 5 patents and again may run into significant IP issues. Titan on the other hand is anticipating FDA approval in 2023, has almost 180 patents or patent pending. The patents that are the most important have freedom to operate and many of which are deemed desirable from the biggest player in the market other than Intuititve and you think they are a 200-300 million company? 1 and 1 does not equal 2 evidently.
Well…….. we’re waiting!!!!!
Explain yourself how do you come up with a 200-300 million valuation at the end?